Frontlight ResearchEarly access
Taking people in United StatesPhase 1
Islet Function in Gestational Diabetes
Key facts
- Who runs it
- Mayo Clinic
- Where
- Rochester, United StatesSee the site
- Trial code
- Status
- Recruiting
- Phase
- Phase 1
- People taking part
- 90 people, planned
- Started
- Sept 2026
- Expected to end
- Dec 2030
- Type of study
- Interventional, 2 groups
- Treatments tested
- Exendin 9-39
- Record updated
- 8 September 2026
Who can take part
- Age
- 20 years to 40 years
- Sex
- Women only
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 12 criteriaShow less
Who can take part
- Pregnant individuals with a viable singleton pregnancy who have completed second trimester gestational diabetes screening and are eligible for classification as either gestational diabetes mellitus or no gestational diabetes mellitus
- Participants must be willing and able to provide informed consent and complete planned pregnancy and postpartum study visits
Who cannot take part
- Active systemic illness (e.g. chronic kidney disease, hypertension)
- Pre-pregnancy diabetes mellitus
- History of upper gastrointestinal surgery that alters gastric emptying (e.g. bariatric surgery)
- Fasting glucose ≥ 100 mg/dL or HbA1c ≥ 5.7% in early pregnancy
- One abnormal value on the 3-hour 100 g oral glucose tolerance test
- Glucose at least 190 mg/dL on glucose challenge testing without subsequent 3-hour oral glucose tolerance testing
- Use of medication affecting glucose metabolism before pregnancy or in early pregnancy
- Use of glucose-lowering medication (e.g. metformin, glyburide) other than insulin to treat gestational diabetes mellitus in the current pregnancy
- Hemoglobin < than 11 g/dL
- Multiple gestation, major fetal anomaly, or non-viable pregnancy on ultrasound
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 20 and 40 years old?
Where in United States
- Mayo ClinicRochester, United StatesContact: Jeanette LaugenTaking people
About the trial
What the trial wants to find out
The purpose of this research is to understand how the function of the human pancreas changes during and after pregnancy.
The 2 groups in the trial
- Women With Gestational Diabetes MellitusTreatment being tested
Pregnant participants diagnosed with gestational diabetes mellitus who complete pregnancy and postpartum metabolic study visits.
Treatment: Exendin 9-39
- Women Without Gestational Diabetes MellitusTreatment being tested
Pregnant participants without gestational diabetes mellitus, matched to the gestational diabetes group by parity, age, ethnicity, gestational week at diagnosis comparator timepoint, and first trimester body mass index.
Treatment: Exendin 9-39
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Fit questions
- Built from NCT07806695, who can take part
- Record updated
- 8 September 2026